134 related articles for article (PubMed ID: 8931119)
21. Effects of chronic treatment with indomethacin at clinically relevant doses on intestinal tissue 6-keto prostaglandin F1 alpha and leukotriene B4 level in relation to gastroenteropathy.
Uçar A; Sak SD; Melli M
Inflammation; 1998 Jun; 22(3):243-52. PubMed ID: 9604712
[TBL] [Abstract][Full Text] [Related]
22. Effects of novel anti-inflammatory compounds on healing of acetic acid-induced gastric ulcer in rats.
Lesch CA; Gilbertsen RB; Song Y; Dyer RD; Schrier D; Kraus ER; Sanchez B; Guglietta A
J Pharmacol Exp Ther; 1998 Oct; 287(1):301-6. PubMed ID: 9765350
[TBL] [Abstract][Full Text] [Related]
23. Effects of non-steroidal anti-inflammatory drugs on rat gastric mucosal leukotriene C4 and prostanoid release: relation to ethanol-induced injury.
Peskar BM; Hoppe U; Lange K; Peskar BA
Br J Pharmacol; 1988 Apr; 93(4):937-43. PubMed ID: 3390662
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.
Melarange R; Blower P; Spangler R
Eur J Rheumatol Inflamm; 1994; 14(2):23-7. PubMed ID: 7744130
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.
Giuliano F; Ferraz JG; Pereira R; de Nucci G; Warner TD
Eur J Pharmacol; 2001 Aug; 426(1-2):95-103. PubMed ID: 11525777
[TBL] [Abstract][Full Text] [Related]
26. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
[TBL] [Abstract][Full Text] [Related]
27. The effect of nabumetone and indomethacin on gastric mucosal function.
Shorrock CJ; Rees WD
J Rheumatol Suppl; 1992 Nov; 36():85-8. PubMed ID: 1474543
[No Abstract] [Full Text] [Related]
28. The anti-inflammatory effect of FR188582, a highly selective inhibitor of cyclooxygenase-2, with an ulcerogenic sparing effect in rats.
Ochi T; Yamane-Sugiyama A; Ohkubo Y; Sakane K; Tanaka H
Jpn J Pharmacol; 2001 Feb; 85(2):175-82. PubMed ID: 11286400
[TBL] [Abstract][Full Text] [Related]
29. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.
Mangan FR; Flack JD; Jackson D
Am J Med; 1987 Oct; 83(4B):6-10. PubMed ID: 3688000
[TBL] [Abstract][Full Text] [Related]
30. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation.
Kirchner T; Aparicio B; Argentieri DC; Lau CY; Ritchie DM
Prostaglandins Leukot Essent Fatty Acids; 1997 Jun; 56(6):417-23. PubMed ID: 9223651
[TBL] [Abstract][Full Text] [Related]
31. Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
Spangler RS
Am J Med; 1993 Aug; 95(2A):35S-39S. PubMed ID: 8357001
[TBL] [Abstract][Full Text] [Related]
32. Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats.
Tibble J; Sigthorsson G; Caldwell C; Palmer RH; Bjarnason I
Aliment Pharmacol Ther; 2001 Dec; 15(12):2001-8. PubMed ID: 11736732
[TBL] [Abstract][Full Text] [Related]
33. Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo.
Reichman J; Cohen S; Goldfarb M; Shina A; Rosen S; Brezis M; Karmeli F; Heyman SN
Exp Nephrol; 2001; 9(6):387-96. PubMed ID: 11701998
[TBL] [Abstract][Full Text] [Related]
34. Effects of nabumetone and dipyrone on experimentally induced gastric ulcers in rats.
Yıldırım E; Sağıroğlu O; Kılıç FS; Erol K
Inflammation; 2013 Apr; 36(2):476-81. PubMed ID: 23129452
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
[TBL] [Abstract][Full Text] [Related]
37. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
Friedel HA; Langtry HD; Buckley MM
Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
[TBL] [Abstract][Full Text] [Related]
38. Effects of nabumetone, a new non-steroidal anti-inflammatory drug, on urinary prostaglandin excretion in man.
Giannessi D; Lazzerini G; Filipponi P; Mannarelli C; Vaiani G; Grossi E; De Caterina R
Pharmacol Res; 1993; 28(3):229-41. PubMed ID: 8108313
[TBL] [Abstract][Full Text] [Related]
39. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man.
Bjarnason I; Fehilly B; Smethurst P; Menzies IS; Levi AJ
Gut; 1991 Mar; 32(3):275-7. PubMed ID: 1901563
[TBL] [Abstract][Full Text] [Related]
40. In vitro investigation of the effects of cyclooxygenase-2 inhibitors on contractile activity of the equine dorsal and ventral colon.
Van Hoogmoed LM; Snyder JR; Harmon FA
Am J Vet Res; 2002 Nov; 63(11):1496-500. PubMed ID: 12428657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
